Approval · Notice of Compliance 27354 · 2022
LIBRAX: Notice of Compliance 27354
Issued January 7, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27354
- Date
- January 7, 2022
- Company
- Bausch Health, Canada Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the design of bottle labels and align with plain language labelling regulations.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LIBRAX | Not yet assigned | — |
Medicinal ingredients
- CHLORDIAZEPOXIDE HCL 5 MG per CAP
- CLIDINIUM BROMIDE 2.5 MG per CAP